COVID-19 vaccine development continues to be the subject of political jostling, with President Trump contradicting top U.S. health officials regarding timeline and efficacy. The Centers for Disease Control and Prevention say they expect to distribute vaccines publicly at no cost to the patient. But what will the government pay, and how much could drug companies profit? Paul Solman reports.

PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

U.S. airlines are sending out warnings about huge financial losses and urgently requesting help. Tens of thousands of flights for the fall have been canceled, and change fees have been eliminated in order to attract travelers. Meanwhile, flight staff and security are being drawn into arguments with passengers who refuse to comply with mask mandates. Economics correspondent Paul Solman reports. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

Throughout the Republican National Convention, supporters of President Trump have touted his economic record as a key reason they believe he should be reelected. But what would a second-term policy agenda look like for Trump, as the coronavirus pandemic continues to limit economic growth and threaten American jobs? Paul Solman reports on Trump’s record so far and proposals for the future. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

With tens of millions of Americans reeling financially from the coronavirus pandemic, the future of the U.S. economy is on the minds of many. Both President Trump and Democratic challenger Joe Biden are seeking to convince voters they can revive the country. But what do their respective policies suggest? Paul Solman analyzes some of Biden’s key economic proposals -- and how he would pay for them. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

The antibiotics industry has suffered an alarming collapse that has become even more troubling as secondary bacterial infections threaten patients with COVID-19. Why has production of these vital medicines stagnated, and what can be done to address the problem? Economics correspondent Paul Solman reports on why lifesaving drugs don't necessarily translate to lucrative businesses.

PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

COVID-19 can be accompanied by secondary bacterial infections with deadly consequences. But the industry that researches and produces antibiotics to fight such illnesses has been upended -- and the pandemic is only making things worse. Now, medical experts worry about the long-term health implications of not having cutting-edge antibiotics in the pharmaceutical pipeline. Paul Solman reports. PBS NewsHour is supported by - https://www.pbs.org/newshour/about/funders

In the U.S., child care was expensive and difficult to obtain long before the pandemic. But coronavirus has closed schools, forced parents to work from home and shuttered some care facilities for good. With COVID-19 surging in much of the country, many parents may not be able to return to the workforce full-time. Paul Solman reports on the dilemma they face -- and its economic repercussions. PBS NewsHour is supported by - https://www.pbs.org/newshour/about/funders

The coronavirus pandemic has shed new light on racial disparities in American health outcomes. Economic disadvantage is one reason Black people in the United States are on average less healthy than white people -- but there are other causes, including the ongoing stress of systemic racism. Paul Solman reports in the second of a two-part Race Matters series. PBS NewsHour is supported by - https://www.pbs.org/newshour/about/funders

African Americans face immense disparities across a broad range of categories, including economic. That history of disadvantage is making the current problems of COVID-19 even worse. Economics correspondent Paul Solman reports. PBS NewsHour is supported by - https://www.pbs.org/newshour/about/funders

Long before the coronavirus pandemic, manufacturing in the U.S. was transformed -- and with it, daily life. Now COVID-19 is delivering a new blow to the industry. But some companies are pivoting to create the personal protective equipment that the U.S. had previously outsourced overseas. Paul Solman reports on how a family textile business nearly 200 years old is adapting to this latest challenge. PBS NewsHour is supported by - https://www.pbs.org/newshour/about/funders